Denali Therapeutics Inc (DNLI)

Feb 6, 2025, 11:42 AM EST - 16 days ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Jan 15, 2025, 2:26 PM EST - 5 weeks ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 9, 2025, 3:56 PM EST - 6 weeks ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 6, 2025, 4:43 PM EST - 6 weeks ago

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:30 PM EST - 6 weeks ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 3, 2025, 1:08 PM EST - 7 weeks ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Nov 16, 2024, 8:56 AM EST - 3 months ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 6, 2024, 4:01 PM EST - 3 months ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Sep 3, 2024, 8:00 AM EDT - 6 months ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Aug 19, 2024, 10:55 PM EDT - 6 months ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 14, 2024, 2:00 PM EDT - 6 months ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 1, 2024, 6:45 AM EDT - 7 months ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jun 3, 2024, 8:00 AM EDT - 9 months ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

May 13, 2024, 12:30 PM EDT - 10 months ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 7, 2024, 4:01 PM EDT - 10 months ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 10 months ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Mar 6, 2024, 10:05 PM EST - 1 year ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Feb 27, 2024, 8:05 AM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 7, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Jan 8, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Nov 7, 2023, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 2, 2023, 5:26 AM EDT - 1 year ago

Denali's New Summit: Changing Hunter Syndrome Landscape

Sep 11, 2023, 6:30 AM EDT - 1 year ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA OMGA SANA

Aug 30, 2023, 8:30 AM EDT - 1 year ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 23, 2023, 12:51 AM EDT - 1 year ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jun 21, 2023, 6:00 AM EDT - 1 year ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

FHTX MCRB MRNA OMGA SANA

Jun 20, 2023, 7:00 AM EDT - 1 year ago

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

May 8, 2023, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 17, 2023, 6:52 AM EDT - 2 years ago

Denali Therapeutics: Pioneering The Neurodegenerative Space With Blood-Brain Barrier Innovations

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Feb 27, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Feb 22, 2023, 4:33 PM EST - 2 years ago

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

Feb 15, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Jan 25, 2023, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

Jan 16, 2023, 12:15 PM EST - 2 years ago

Denali: Need Patient Data To Justify That High Valuation

Jan 9, 2023, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Dec 21, 2022, 10:55 AM EST - 2 years ago

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

ARVN AXSM FATE GTLS RCKT

Dec 5, 2022, 7:00 AM EST - 2 years ago

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

Nov 3, 2022, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

Oct 28, 2022, 7:05 PM EDT - 2 years ago

Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment

Oct 24, 2022, 4:30 PM EDT - 2 years ago

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 19, 2022, 9:19 PM EDT - 2 years ago

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

Oct 18, 2022, 4:40 PM EDT - 2 years ago

Denali Therapeutics Announces Proposed Offering of Common Stock

Oct 3, 2022, 8:00 AM EDT - 2 years ago

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's Disease Associated with LRRK2 Pathogenic Mutations

Aug 31, 2022, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022